AMCP Statement on Rebate Rule Delay
Alexandria, Va., Feb. 1, 2021 — Following the Biden administration’s postponement of the effective date of the elimination of the regulatory safe harbor for retrospective manufacturer rebates, AMCP released the below statement.
“We applaud the Biden administration’s delay of a harmful policy that would significantly increase premiums for 90% of Medicare Part D recipients and potentially destabilize the program. AMCP is firmly opposed to this rebate rule, and calls on the Biden administration to complete their review and permanently repeal this rule.
“The impact of this rule would be far-reaching and harmful. In the final days of its tenure, against popular opinion, the Trump administration circumvented the regular rulemaking process to make a last ditch effort to implement a rule that would increase costs for seniors and cost taxpayers hundreds of billions of dollars over the next decade.
“We look forward to continuing to work with the Biden administration and our partners to find real solutions ensuring patients have access to the medications they need at costs they can afford.”
The Biden administration took this action following a lawsuit by the Pharmaceutical Care Management Association (PCMA) challenging the Medicare Part D rebate rule.
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models. Visit www.amcp.org.